Summary & Overview
HCPCS Level II C9087: Injection, Cyclophosphamide (auromedics), 10 mg
HCPCS Level II code C9087 denotes a 10 mg unit of injectable cyclophosphamide (auromedics), a chemotherapeutic agent used in multiple oncologic and immunologic indications. Nationally, accurate coding for unit-based chemotherapy agents is essential for consistent drug billing, inventory tracking, and payer claims adjudication. The code matters because it affects facility and professional reimbursement for drug acquisition and administration costs, and it plays a role in utilization monitoring for high-cost oncology treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for cyclophosphamide injections, common sites of service for administration, and the coding implications of a unit-based HCPCS Level II drug code. The report also outlines expected benchmarks and policy considerations relevant to billing and coverage for injectable chemotherapy agents, and highlights areas where payer policy language can affect claim adjudication and prior authorization requirements.
This summary is intended to inform billing professionals, clinicians involved in chemotherapy administration, and policy analysts about the practical significance of HCPCS Level II code C9087 in national billing and coverage workflows.
Billing Code Overview
HCPCS Level II code C9087 describes an injection of cyclophosphamide (auromedics), 10 mg. This code represents administration of a chemotherapeutic agent in a measured 10 mg unit.
Service type: Therapeutic drug administration (chemotherapy)
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office administering injectable chemotherapy
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with relapsed ovarian carcinoma presents to an outpatient oncology infusion center for systemic chemotherapy. The oncologist prescribes intravenous cyclophosphamide (auromedics) dosed per body surface area; the pharmacy prepares vials and documents dispensing as C9087 billed per 10 mg unit. The patient is assessed by the infusion nurse for pre-medication needs, venous access is confirmed (peripheral IV or implanted port), baseline vital signs and laboratory results (complete blood count, renal and liver panels) are reviewed for treatment safety. The infusion is administered under oncology nursing supervision with monitoring for acute infusion reactions, hemorrhagic cystitis prevention measures (e.g., mesna if indicated by regimen), and post-infusion instructions provided. Documentation includes indication, lot numbers, dose in milligrams, total units billed, route, site of service (typically outpatient hospital infusion center or physician office), relevant ICD-10 diagnosis, and any applicable modifier(s).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when cyclophosphamide administration requires substantially greater resources than usual due to complexity or documentation supports increased work. |